China National Medicines' (SHA:600511) net profit attributable to shareholders in 2025 slipped 0.2% year on year to nearly 2 billion yuan, according to a Shanghai bourse filing on Friday.
Earnings per share were flat at 2.65 yuan.
Operating revenue rose 3.7% to 52.5 billion yuan from 50.6 billion yuan in the preceding year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.